Transapical approach to endovascular surgical repair of aortic dissections using a modified stent.
- Minimally invasive, controllable method of device delivery allows for endovascular repair.
- The stent can be modified to account for the aortic condition being treated.
- A unique feature of this device is the method and location of introduction as most existing devices of this nature are introduced through the femoral artery.
Aortic aneurisms and aortic dissections can occur in the descending, ascending or transverse arch of the aorta. One feature of aortic dissections is a tear in the intimal layer of the aorta, followed by formation of a hematoma that may occupy a significant circumference of the aorta, thereby causing a life-threatening condition.
Currently, aortic dissections are repaired surgically using a procedure that requires a surgeon to open the chest cavity, clamp off the aorta, and repair the dissection by attaching a graft to the site, often while inducing profound hypothermic levels in the patient. Alternatives to this procedure include endovascular repair involving the insertion of a suitable endoscopic device through the femoral artery, allowing for minimally invasive surgical repair, though these devices are not suitable for repair of type A aortic dissections.
Dr. Omar Lattouf has developed a modified stent and delivery system for minimally invasive repair of aortic dissections that occur in the ascending portion of the aorta (i.e., type A). The stent is delivered through the left ventricular apex of the heart, and once deployed, corrects the aortic dissection by compressing the hematoma, which is characteristic of a type a dissection, against the aortic wall. Thus, blood flow is restored to full capacity. Importantly, the stent is designed such that blood flow to critical vessels in the ascending aorta is not inhibited.
Developmental Stage & Potential Market
- Aortic dissection occurs in approximately 2 out of every 10,000 people.
- By the end of 2006 the global market for thoracic aortic stent grafts and access devices was estimated at $70 million; the market is forecasted to reach $250 million globally by 2012.